Literature DB >> 16487618

Clinical characteristics and prognostic markers in disulfiram-induced liver injury.

Einar Björnsson1, Hans Nordlinder, Rolf Olsson.   

Abstract

BACKGROUND/AIMS: Limited systematic data exists on the incidence of drug-induced hepatotoxicity due to disulfiram and the most important prognostic markers. We aimed to determine the nature and frequency of suspected disulfiram hepatotoxicity in Sweden.
METHODS: All reports of suspected hepatic adverse drug reactions (ADR) associated with disulfiram received by the Swedish Adverse Drug Reactions Advisory Committee (SADRAC) 1966-2002 were reviewed. Causality assessment was based on the International Consensus Criteria.
RESULTS: A total of 82 reports of disulfiram suspected ADRs had at least a possible causal relationship. Eight patients died or underwent liver transplantation (Tx). Mortality or Tx was 16% in patients with jaundice. The median age of the patients (65% males) was 45 years with a median duration of treatment of 42 days. Bilirubin was higher (P<0.0001) in the deceased/transplanted patients compared to surviving patients. No difference was observed in age or duration of therapy between deceased and transplanted and those who recovered. Eosinophilic infiltration in liver biopsies was associated with a favourable outcome, hepatocyte drop-out with a poor outcome.
CONCLUSIONS: Disulfiram associated hepatitis has a considerable mortality risk. Histological signs of immunoallergy seem to be common. Bilirubin and hepatocyte drop-out were the only predictors for death or transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487618     DOI: 10.1016/j.jhep.2005.12.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?

Authors:  Carmen Verge; M Isabel Lucena; Enrique López-Torres; M José Puche-Garcia; Enrique Fraga; Manuel Romero-Gomez; Raúl J Andrade
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

Review 2.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 3.  Outpatient management of alcohol-related liver disease.

Authors:  Douglas A Simonetto; Vijay H Shah; Patrick S Kamath
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05

Review 4.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 5.  Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options.

Authors:  Tawfik Khoury; Ayman Abu Rmeileh; Liron Yosha; Ariel A Benson; Saleh Daher; Meir Mizrahi
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

6.  Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo.

Authors:  Remco van Dijk; Sem J Aronson; Dirk R de Waart; Stan F van de Graaf; Suzanne Duijst; Jurgen Seppen; Ronald Oude Elferink; Ulrich Beuers; Piter J Bosma
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

Review 7.  The past and present of serum aminotransferases and the future of liver injury biomarkers.

Authors:  Mitchell R McGill
Journal:  EXCLI J       Date:  2016-12-15       Impact factor: 4.068

Review 8.  MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  J Clin Med       Date:  2015-05-20       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.